Cell Biology Section, Division of Intramural Research, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland.
Trans-NIH Shared Resource on Biomedical Engineering and Physical Science, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland.
Biophys J. 2019 Feb 19;116(4):670-683. doi: 10.1016/j.bpj.2019.01.009. Epub 2019 Jan 12.
Durotaxis is a type of directed cell migration in which cells respond to a gradient of extracellular stiffness. Using automated tracking of positional data for large sample sizes of single migrating cells, we investigated 1) whether cancer cells can undergo durotaxis; 2) whether cell durotactic efficiency varies depending on the regional compliance of stiffness gradients; 3) whether a specific cell migration parameter such as speed or time of migration correlates with durotaxis; and 4) whether Arp2/3, previously implicated in leading edge dynamics and migration, contributes to cancer cell durotaxis. Although durotaxis has been characterized primarily in nonmalignant mesenchymal cells, little is known about its role in cancer cell migration. Diffusible factors are known to affect cancer cell migration and metastasis. However, because many tumor microenvironments gradually stiffen, we hypothesized that durotaxis might also govern migration of cancer cells. We evaluated the durotactic potential of multiple cancer cell lines by employing substrate stiffness gradients mirroring the physiological stiffness encountered by cells in a variety of tissues. Automated cell tracking permitted rapid acquisition of positional data and robust statistical analyses for migrating cells. These durotaxis assays demonstrated that all cancer cell lines tested (two glioblastoma, metastatic breast cancer, and fibrosarcoma) migrated directionally in response to changes in extracellular stiffness. Unexpectedly, all cancer cell lines tested, as well as noninvasive human fibroblasts, displayed the strongest durotactic migratory response when migrating on the softest regions of stiffness gradients (2-7 kPa), with decreased responsiveness on stiff regions of gradients. Focusing on glioblastoma cells, durotactic forward migration index and displacement rates were relatively stable over time. Correlation analyses showed the expected correlation with displacement along the gradient but much less with persistence and none with cell speed. Finally, we found that inhibition of Arp2/3, an actin-nucleating protein necessary for lamellipodial protrusion, impaired durotactic migration.
趋硬性是一种定向细胞迁移,其中细胞对外界基质硬度梯度做出反应。我们使用自动化追踪方法获取大量单细胞迁移的位置数据,研究了 1)癌细胞是否能够发生趋硬性;2)细胞趋硬性效率是否取决于硬度梯度的区域顺应性;3)特定的细胞迁移参数(如速度或迁移时间)是否与趋硬性相关;以及 4)先前被认为与前缘动力学和迁移有关的 Arp2/3 是否有助于癌细胞趋硬性。尽管趋硬性已主要在非恶性间充质细胞中得到了描述,但对于其在癌细胞迁移中的作用知之甚少。众所周知,可扩散因子会影响癌细胞的迁移和转移。然而,由于许多肿瘤微环境逐渐变硬,我们假设趋硬性也可能控制癌细胞的迁移。我们通过使用与细胞在各种组织中遇到的生理硬度相匹配的基质硬度梯度来评估多种癌细胞系的趋硬性潜力。自动化细胞追踪允许快速获取位置数据,并对迁移细胞进行强大的统计分析。这些趋硬性测定表明,测试的所有癌细胞系(两种神经胶质瘤、转移性乳腺癌和纤维肉瘤)均在外源基质硬度变化时表现出定向迁移。出乎意料的是,所有测试的癌细胞系以及非侵袭性的人成纤维细胞,在硬度梯度最软的区域(2-7kPa)表现出最强的趋硬性迁移反应,而在梯度较硬的区域反应性降低。关注神经胶质瘤细胞,趋硬性向前迁移指数和位移率随时间相对稳定。相关分析显示与沿梯度的位移存在预期的相关性,但与持久性相关性较小,与细胞速度无关。最后,我们发现抑制肌动蛋白成核蛋白 Arp2/3 会损害趋硬性迁移,该蛋白对于片状伪足的延伸是必需的。